Adamas Pharmaceuticals, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4a90a56b-bcf4-404b-8bb6-355c67c86a7e/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2020 | $74.5M | 2020-01-01 – 2020-12-31 | evidence 0001328143-21-000019 |
| FY 2019 | $54.6M | 2019-01-01 – 2019-12-31 | evidence 0001328143-20-000012 |
| FY 2018 | $34.0M | 2018-01-01 – 2018-12-31 | evidence 0001328143-19-000011 |
| FY 2017 | $571.0k | 2017-01-01 – 2017-12-31 | evidence 0001328143-19-000011 |
| FY 2016 | $572.0k | 2016-01-01 – 2016-12-31 | evidence 0001328143-19-000011 |
| FY 2015 | $0 | 2015-01-01 – 2015-12-31 | evidence 0001628280-18-002045 |
| FY 2014 | $55.8M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-001576 |
| FY 2013 | $71.1M | 2013-01-01 – 2013-12-31 | evidence 0001047469-15-001576 |
| FY 2012 | $37.5M | 2012-01-01 – 2012-12-31 | evidence 0001047469-15-001576 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Adamas Pharmaceuticals, Inc. — all facts · Net Income · Operating Income